My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 742

    1.

    Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated).

    Shorr AF, Nelson DR, Wyncoll DL, Reinhart K, Brunkhorst F, Vail GM, Janes J.

    Crit Care. 2008;12(2):R45. Epub 2008 Apr 4. Review.PMID: 18394162 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

    Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61. PMID: 17084715 [PubMed - indexed for MEDLINE]Related articles

    3.

    The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

    Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2004 Nov;32(11):2199-206.PMID: 15640631 [PubMed - indexed for MEDLINE]Related articles

    4.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

    Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

    Surgery. 2007 Apr;141(4):548-61.PMID: 17431957 [PubMed - indexed for MEDLINE]Related articles

    5.

    Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

    Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

    N Engl J Med. 2005 Sep 29;353(13):1332-41.PMID: 16192478 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

    Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

    Crit Care Med. 2008 Jan;36(1):14-23.PMID: 18158435 [PubMed - indexed for MEDLINE]Related articles

    7.

    ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.

    Goldstein B, Nadel S, Peters M, Barton R, Machado F, Levy H, Haney DJ, Utterback B, Williams MD, Giroir BP.

    Pediatr Crit Care Med. 2006 May;7(3):200-11.PMID: 16575354 [PubMed - indexed for MEDLINE]Related articles

    8.

    Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

    Vincent JL, Nadel S, Kutsogiannis DJ, Gibney RT, Yan SB, Wyss VL, Bailey JE, Mitchell CL, Sarwat S, Shinall SM, Janes JM.

    Crit Care. 2005 Aug;9(4):R331-43. Epub 2005 May 17.PMID: 16137345 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

    Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

    Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.PMID: 15774234 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.

    Sashegyi A, Trzaskoma BL, Nelson DR, Williams MD, Macias W.

    Curr Med Res Opin. 2006 May;22(5):1001-12.PMID: 16709322 [PubMed - indexed for MEDLINE]Related articles

    11.

    International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.

    Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD, Levy M, Levi M, Utterback B, Vincent JL.

    J Crit Care. 2007 Jun;22(2):142-52. Epub 2007 Jan 31.PMID: 17548026 [PubMed - indexed for MEDLINE]Related articles

    12.

    Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis.

    Laterre PF, Macias WL, Janes J, Williams MD, Nelson DR, Girbes AR, Dhainaut JF, Abraham E.

    Crit Care. 2008;12(5):R117. Epub 2008 Sep 11.PMID: 18786266 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis.

    Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP.

    Crit Care. 2006;10(3):R74. Epub 2006 May 9.PMID: 16684364 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

    Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

    Crit Care Med. 2003 Jan;31(1):12-9.PMID: 12544987 [PubMed - indexed for MEDLINE]Related articles

    15.

    Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.

    Hodder RV, Hall R, Russell JA, Fisher HN, Lee B.

    Crit Care. 2009;13(3):R78. Epub 2009 May 20.PMID: 19457240 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    The protein C pathway: implications for the design of the RESPOND study.

    Vangerow B, Shorr AF, Wyncoll D, Janes J, Nelson DR, Reinhart K.

    Crit Care. 2007;11 Suppl 5:S4. Review.PMID: 18269691 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Drotrecogin alfa (activated): real-life use and outcomes for the UK.

    Rowan KM, Welch CA, North E, Harrison DA.

    Crit Care. 2008;12(2):R58. Epub 2008 Apr 22.PMID: 18430215 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

    Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group.

    Lancet. 2007 Mar 10;369(9564):836-43.PMID: 17350452 [PubMed - indexed for MEDLINE]Related articles

    19.

    Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.

    Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC.

    Crit Care Med. 2004 Nov;32(11):2207-18.PMID: 15640632 [PubMed - indexed for MEDLINE]Related articles

    20.

    The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.

    Martin G, Brunkhorst FM, Janes JM, Reinhart K, Sundin DP, Garnett K, Beale R.

    Crit Care. 2009;13(3):R103. Epub 2009 Jun 30.PMID: 19566927 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity